Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.

① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.

cls.cnDec 22 11:45

ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication

Seeking AlphaDec 23 23:07

Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250

Futu NewsDec 21 18:33 · Ratings

Sector Update: Health Care Stocks Fall Premarket Monday

MT NewswiresDec 23 22:21

Does Eli Lilly (NYSE:LLY) Deserve A Spot On Your Watchlist?

Simply Wall StDec 23 21:58

Express News | Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea

BreakingsDec 23 21:14